Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 4 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 4Uveal Melanoma 1Cholangiocarcinoma 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Sirtuins × Clear all
NCT06904196 2025-04-29

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
78 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06707233 2025-01-28

Y-90 SIRT for Unresectable HCC Larger Than 7cm

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05992584 2023-09-14

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01126645 2019-05-31

SORAMIC

University of Magdeburg

Phase 2 Completed
529 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡